{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T10:31:11Z","timestamp":1772706671820,"version":"3.50.1"},"reference-count":30,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aust J Dermatology"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Psoriasis imposes a disease burden that can have a profound negative impact on patients' quality of life (QoL). HOPE was the first non\u2010interventional study conducted in patients with severe chronic plaque psoriasis in Australia that evaluated health\u2010related QoL in response to treatment with secukinumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>HOPE was a prospective, open\u2010label, single\u2010arm, multicentre, non\u2010interventional, exploratory study in patients with severe chronic plaque psoriasis in Australia. The study investigated the change in QoL, using the Dermatology Life Quality Index (DLQI), Assessment Quality of Life\u20108 Dimension questionnaire (AQoL\u20108D) and Psoriasis Area and Severity Index (PASI), and safety profile in response to treatment with secukinumab 300\u2009mg SC weekly for 4\u2009weeks followed by monthly maintenance for 58\u2009weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At Week 14, the mean percentage reduction in total DLQI score from baseline was \u221282.4% (<jats:italic>n<\/jats:italic>\u00a0=\u200965), which indicates a substantial improvement in QoL. This level of improvement was sustained up to Week \u226558, with a mean percentage change of \u221287.4%. The mean percentage change from baseline for AQoL\u20108D weighted total score decreased from Week 14 (41.1%) to Week 58 (35.2%), indicating an improvement in patients' QoL. A high proportion of patients achieved PASI 75\/90\/100 responses at Week 14 (97.0%\/71.2%\/34.8%), with rates sustained up to Week \u226558 (100%\/87.9%\/43.1%). The safety profile of secukinumab was favourable, with no cumulative or unexpected safety concerns.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Secukinumab treatment demonstrated a striking improvement in patients' QoL in the HOPE study, the first real\u2010world study in patients with severe chronic plaque psoriasis in the Australian clinical setting.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ajd.13893","type":"journal-article","created":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T18:00:11Z","timestamp":1657562411000},"page":"312-320","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Secukinumab treatment showed improved quality of life in patients with chronic plaque psoriasis in Australia: Results from the <scp>HOPE<\/scp> study"],"prefix":"10.1111","volume":"63","author":[{"given":"Peter","family":"Foley","sequence":"first","affiliation":[{"name":"Skin Health Institute Inc.  Carlton Victoria Australia"},{"name":"St Vincent's Department of Medicine (Dermatology), St Vincent's Hospital Melbourne The University of Melbourne  Fitzroy Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynda","family":"Spelman","sequence":"additional","affiliation":[{"name":"Veracity Clinical Research Pty. Ltd.  Woolloongabba Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dedee F.","family":"Murrell","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of New South Wales  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Mate","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Australia Pty. Ltd.  Macquarie Park New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Tronnberg","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Australia Pty. Ltd.  Macquarie Park New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia M.","family":"Lowe","sequence":"additional","affiliation":[{"name":"Royal Prince Alfred Hospital  Camperdown New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,7,11]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/JDN.0000000000000418"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.5114\/reum.2018.80718"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.339"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S200147"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.14744\/nci.2016.16023"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010020\u201000363\u20101"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1159\/000090652"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.07.059"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21051690"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18112297"},{"key":"e_1_2_9_12_1","unstructured":"Cosentyx Australian Prescribing Information.Novartis Pharmaceuticals Australia.2016. Available fromhttps:\/\/www.tga.gov.au\/sites\/default\/files\/auspar\u2010secukinuma\u2010161025\u2010pi.pdf(2020). (Accessed 20 February 2020)."},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00460"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(08)60725\u20104"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S100940"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2018.1445223"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S146640"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S165943"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412679"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.08.008"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14878"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1708897"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16558"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2011.2768"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16632"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15962"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40271\u2010013\u20100036\u2010x"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000001163"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010018\u20100265\u2010y"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12106"}],"container-title":["Australasian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajd.13893","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajd.13893","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajd.13893","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T14:34:34Z","timestamp":1692628474000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajd.13893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,11]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1111\/ajd.13893"],"URL":"https:\/\/doi.org\/10.1111\/ajd.13893","archive":["Portico"],"relation":{},"ISSN":["0004-8380","1440-0960"],"issn-type":[{"value":"0004-8380","type":"print"},{"value":"1440-0960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,11]]},"assertion":[{"value":"2022-03-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}